Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 5/20 | 0.39 |
| ▸ | ACHE | P22303 | 5/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | NNMT | P40261 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2994920 | 0.91 | BCHE (0.47) | BCHEACHEOPRM1OPRK1OPRD1 | |
| SCHEMBL2988184 | 0.83 | OPRK1 (0.44) | OPRM1OPRK1OPRD1 | |
| SCHEMBL2988787 | 0.81 | OPRK1 (0.45) | OPRM1OPRK1OPRD1CNR1 | |
| SCHEMBL2994340 | 0.79 | ALDH1A1 (0.40) | ALDH1A1BCHEACHEOPRM1OPRK1 | |
| SCHEMBL2987566 | 0.79 | OPRK1 (0.43) | OPRM1OPRK1OPRD1NNMT | |
| SCHEMBL2986995 | 0.78 | OPRM1 (0.42) | OPRM1OPRK1OPRD1 | |
| SCHEMBL14026652 | 0.76 | NNMT (0.50) | OPRM1OPRK1OPRD1NNMT | |
| SCHEMBL2980646 | 0.76 | OPRK1 (0.47) | OPRM1OPRK1OPRD1NNMT | |
| SCHEMBL6223567 | 0.75 | ABCB1 (0.41) | OPRM1OPRK1OPRD1 | |
| SCHEMBL2991647 | 0.75 | NNMT (0.40) | OPRM1OPRK1OPRD1NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278442-B2 | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders | PROSIDION LIMITED (GB) | 2012-10-02 | — | — | US | claimed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | claimed |
| US-8278442-B2 | Bicyclic aryl and heteroaryl compounds for the treatment of metabolic disorders | PROSIDION LIMITED (GB) | 2012-10-02 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-07-08 | — | — | US | disclosed |
| WO-2008142454-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173886-A1 | BICYCLIC ARYL AND HETEROARYL COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | OPRM1, OPRK1, OPRD1 | ALDH1A1 891/4885BCHE 1495/4885ACHE 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.